In just the past 8 years since we launched this report, the 5-year survival rate has gone from 18% to nearly 30%,” said Harold Wimmer, President and CEO of the American Lung Association. In the US, ...

Novel combination achieves 60.8% response rate and 90.2% disease control rate in first-line non-small cell lung cancer (1L NSCLC) Notably, ~92% of all evaluable patients have PD-L1 TPS <50%, including ...

University of Queensland researcher Arutha Kulasinghe studied lung biopsies from the tumours of almost 250 patients with non-small cell lung cancer across Australia, the United States and Europe.

Merck & Co.’s subcutaneous (SC) formulation of Keytruda has matched up to the original intravenous (IV) version on two blood concentration measurements, paving way for a potential FDA approval that ...

TORONTO — Five-year survival rates for people with lung cancer have doubled since the 1990s, but the disease still kills more patients than any other type of cancer, a Statistics Canada report said on ...

– The First Pivotal Phase 3 Trial to Demonstrate Superiority of a TROP-2 Antibody-Drug Conjugate, Trodelvy, Plus Keytruda Versus Standard of Care Keytruda plus Chemotherapy in 1L mTNBC – – Trodelvy ...

Akeso has shared for the first time overall survival data from a high-profile Keytruda head-to-head trial for its PD-1xVEGF bispecific ivonescimab—and investors in the company's partner Summit ...

Despite improvements in survival and early detection rates, Pennsylvania still faces challenges with high smoking rates and ...

Pharma companies are spending billions on a treatment based off old drugs, with little evidence it will extend lives.

Rahway, New Jersey Thursday, November 20, 2025, 14:00 Hrs [IST] ...

Keytruda with paclitaxel, with or without Avastin, improved PFS and OS in PRROC patients, irrespective of PD-L1 status. The trial showed significant benefits in both CPS ≥1 and intention-to-treat ...